NRC FORM 591M PART 1
(11-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Mayo Clinic Rochester Mayo Clinic Rochester Campus Rochester, MN REPORT NUMBER(S) 2005-001	Region III 2443 Warrenville Rd Lisle, IL 60432

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03 C 0 2195	22-00519-03	10/18-21/05

LICENSEE:
The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☑ 2. Previous violation(s) closed.

☐ 3. The violations(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ non-cited violation(s) were discussed involving the following requirement(s):

☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE			
NRC INSPECTOR	Robert G. Gattone, Jr. / Geoffrey Warren	Robert D. Gattone Jr. / Geoffrey Warren	10/21/05

NRC FORM 591M PART 3
(11-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Mayo Clinic Rochester REPORT NUMBER(S) 2005-001	REGION III

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03002195	22-00519-03	10/18-21/05

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87134	03.01, 03.02, 03.03, 03.04, 03.05, 03.06 and 03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02110	1	Richard Vetter, Ph.D., RSO	507-284-4408

☑ Main Office Inspection Next Inspection Date: 10/21/2006

☐ Field Office Inspection

☐ Temporary Job Site Inspection

PROGRAM SCOPE

The licensee conducted licensed activities at its facilities located at the Mayo Clinic Rochester campus, Rochester, Minnesota. The licensee also conducted mobile nuclear medicine at temporary job sites of medical care facilities anywhere in the United States where the NRC maintained jurisdiction for regulating the use of licensed material. Licensed activities included high dose rate (HDR) brachytherapy; activities listed in 10 CFR 35.400 including Cs-137 gynecological treatments, Ir-192 seeds encased in ribbon, I-125 seeds for prostate treatments, and I-125 seeds for eye therapy; mobile nuclear medicine limited to activities listed in 10 CFR 35.200; full spectrum nuclear medicine at Methodist Hospital; cardiac nuclear medicine at the Gonda Building and St. Mary's Cardiac Clinic; primarily diagnostic nuclear medicine at St. Mary's Hospital; research and development primarily involving in-vitro protein labeling with several radionuclides (e.g., P-32, I-125, H-3, S-35, P-33); I-125 iodinations; animal studies; five irradiators for irradiation of blood, tissues, and animal research; and daily incineration of licensed material.

PERFORMANCE OBSERVATIONS

The inspectors observed the administration of licensed material to a human research subject; use of a blood irradiator and a research irradiator; use of the incinerator; incinerator personnel demonstrate a survey of the ash bin; selected staff perform survey meter operability checks; selected staff demonstrate the preparation of a shipping paper for a shipment between licensee facilities; a demonstration of a package receipt survey; licensee staff perform calibration checks of several survey meters; a nuclear medicine technologist demonstrate response to a radioactive spill; selected staff demonstrate how diagnostic and therapeutic radiopharmaceuticals were administered to patients; daily spot checks of an HDR remote afterloader; selected staff demonstrate emergency response to an HDR event; an authorized medical physicist conduct a physics check of an HDR treatment; authorized staff administer an HDR treatment; selected staff demonstrate how the HDR unit was moved between authorized facilities; selected health physics staff conduct periodic audits of selected laboratories; and selected staff conduct removable contamination and ambient exposure rate surveys.